Table 1 List of suggested or existing MSC transplantation research for MS therapy

• To evaluate MRI metrics changes, brain atrophy, number of severe relapses, EDSS, MSFC, quality of life, and RAO test

• Safety

• Efficacy

• To measure the efficacy and safety of IV treatment with autologous MSCs as an MS therapy

• Initial data collection on the effectiveness of experimental therapy in terms of combined MRI operation and therapeutic application (incidence of relapses and worsening of disabilities)

• To assess standard complication questionnaire, MS impact scale MSIS-29, improved SF-36 cell-based therapy track, physical evaluation

• To determine the safety of the injection of MSCs, frequency, the timeline of incidence, and seriousness of harmful effects

• To assess efficacy

• To evaluate some contributors with an alteration in EDSS, neurological disability as assessed by Scripps neurological rating scale, cognitive and leg function, quality of life, and alteration in MRI for spinal cord and brain

• To assess the safety and efficacy in terms of the combined amount of gadolinium-improving lesions in MRI

• To assess visual ability (color and acuity), optic nerve magnetization transfer ratio, visual evoked potential latency,

• To assess retinal nerve fiber layer thickness

• To assess safety and efficacy

• To assess adverse events

• To assess change from baseline in safety and effectiveness by MRI

• To assess the rate of recurrence, duration, and seriousness of undesirable incidence in MSC and placebo groups as determined by CTCAE v4.0 and the overall number of GELs at weeks 4, 12, and 24 after MSC treatment

• To evaluate the effectiveness and safety of BMSCs transplantation in participants with MS.

• To evaluate the lack of unanticipated severe harmful reactions as an assessment of safety and number and size of the lesions on MRI

• To assess isolation and expansion of MSCs,

• To evaluate safety and efficacy assessment pre- and post-treatment

• To assess the safety, the number of participants with adverse events, and tolerability of intrathecal administration with autologous MSCNPs in MS, preliminary evaluation of efficacy

• To assess safety and efficacy

• To evaluate (EDSS) Plus MS functional composite (MSFC) and Bladder function

• To assess the feasibility, safety, and tolerance of autologous MSC injection in participants with relapsing forms of MS

• To assess the tolerance and safety of autologous MSC-NP therapy with progressive MS, N:20

• To assess the percentage of patients with medical enhancement in EDSS score in comparison with standard

• To assess the safety, effectiveness, and adverse events

• To assess tolerance and safety associated with intravenous injection of autologous MSCs

• To assess safety assessment, neurological efficacy

• Efficacy and safety of repeated injection (3 intrathecal dosages) of NurOwn® (MSC-NTF cells)

• To assess migration capability and safety of the injected cells and clinical efficacy in disability score

• To assess adverse events, the cumulative number of MRI Gd-enhancing lesions, MS outbreaks

• To assess efficacy by MRI and safety by vital signs, electrocardiograph monitoring, EDSS, physical inspection, analytical results, and change in quality of life

• To assess the effectiveness and safety of rising dosages of intrathecal SCM-010 in focusses with SPMS

• To assess neurophysiological parameters - combined evoked potentials

• To assess the safety and adverse events of IV infusion of autologous BMSCs in PMS

• To evaluate adverse events and EDSS

• Safety and side effects of high dose MSCs transplantation in terms of pain, hypersensitivity

• Safety of SCs transplantation in terms of infection

• Evaluation of safety and efficacy of Intravenous and Intrathecal injection of autologous BMSCs